Advertisement

Der Nervenarzt

, Volume 81, Issue 7, pp 807–814 | Cite as

Verlaufsmodifizierende Therapien der Alzheimer-Demenz

  • M.T. HenekaEmail author
Leitthema
  • 426 Downloads

Zusammenfassung

Die Behandlung der Alzheimer-Demenz stützt sich aktuell auf symptomatische Therapieansätze. Medikamente, die den Verlauf der Krankheit positiv beeinflussen, befinden sich in verschiedenen Stadien der Entwicklung und klinischen Prüfung. Aufgrund der teilweise ungeklärten Pathogenese sind Rückschläge in der Entwicklung solcher Neuansätze vorprogrammiert. Klinisch-epidemiologische Beobachtungen, die einen neuroprotektiven Effekt von Statinen und nichtsteroidalen Antirheumatika nahelegen, müssen hinsichtlich ihrer molekularen Zusammenhänge weiter aufgeklärt werden. Verlaufsmodifizierende Therapien wirken möglicherweise nur Jahre bis Jahrzehnte vor Beginn der klinischen Apparenz. Daher stellt die Behandlung internistischer Risikofaktoren wie Fettleibigkeit und Hypertonie im mittleren Lebensabschnitt sowie die Ernährung mit mediterraner Diät derzeit eine sinnvolle präventive Maßnahme mit hohem Potenzial zur Verlaufsmodifikation dar.

Schlüsselwörter

Alzheimer-Demenz Fettleibigkeit Mediterrane Diät Hypertonie Neuroprotektion 

Course modifying therapy of Alzheimer’s dementia

Summary

The current therapy of Alzheimer’s disease is primarily symptomatic. Drugs which aim to modify the course of the disease are currently being developed and tested in clinical trials. Given the complex and partly unknown pathogenesis of the disease, failure of such forms of therapy has to be taken into account. Clinical epidemiology suggests a possible neuroprotective effect of statins and non-steroidal anti-inflammatory drugs, however, the molecular basis of these effects has to be further unraveled. Therapies that modify the course of Alzheimer’s disease are only likely to be effective years if not decades before the disease becomes clinically apparent. Thus, the therapy of risk factors including arterial hypertension and obesity in midlife as well as a Mediterranean diet currently provides the highest chance of modifying the course of the disease.

Keywords

Alzheimer’s disease Midlife obesity Mediterranean diet Arterial hypertension Neuroprotection 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Statistisches Bundesamt, Robert-Koch-Institut (2005) Altersdemenz Heft 28Google Scholar
  2. 2.
    IQWiG (2008) Nutzenbewertung von Cholinesterasehemmern, ginkgohaltigen Präparaten und Memantin bei Patienten mit Demenz, auch im Vergleich untereinander, Vorbericht A05–A19Google Scholar
  3. 3.
    Pirtillä T et al (2004) Long-term efficacy and safety of galantamine in patients with mild to moderate Alzheimer‚s disease: A multicenter trial. Eur J Neurol 11:734–741CrossRefGoogle Scholar
  4. 4.
    Heneka MT, O’Banion MK (2007) Inflammatory processes in Alzheimer‚s disease. J Neuroimmunol 184:69–91CrossRefPubMedGoogle Scholar
  5. 5.
    Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297:353–356CrossRefPubMedGoogle Scholar
  6. 6.
    Wolfe MS (2008) Gamma-secretase inhibition and modulation for Alzheimer’s disease. Curr Alzheimer Res 5:158–164CrossRefPubMedGoogle Scholar
  7. 7.
    Green RC et al (2001) Safety and efficacy of tarenflurbil in subjects with mild Alzheimer’s desease: results from an 18-month multi-center phase 3 trial. Alzheimers Demen 4(Suppl 1):165CrossRefGoogle Scholar
  8. 8.
    Aisen PS (2005) The development of anti-amyloid therapy for Alzheimer’s disease: From secretase modulators to polymerisation inhibitors. CNS Drugs 19:989–996CrossRefPubMedGoogle Scholar
  9. 9.
    Gauthier S et al (2009) Effect of tramiprosate in patients with mild-to moderate Alzheimer‚s disease: Exploratory analyses of the MRI subgroup of the Alphase study. J Nutr Health Aging 13:550–557CrossRefPubMedGoogle Scholar
  10. 10.
    Saumier D et al (2009) Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer‚s disease: ADAS-cog subscale results from the Alphase study. J Nutr Health Aging 13:808–812CrossRefPubMedGoogle Scholar
  11. 11.
    Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 3:824–828CrossRefPubMedGoogle Scholar
  12. 12.
    Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193CrossRefPubMedGoogle Scholar
  13. 13.
    Holmes C et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223CrossRefPubMedGoogle Scholar
  14. 14.
    Boche D et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131:3299–3310CrossRefPubMedGoogle Scholar
  15. 15.
    Szabo P et al (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7:415–420CrossRefPubMedGoogle Scholar
  16. 16.
    Salloway S et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer’s disease. Neurology 73:2061–2070CrossRefPubMedGoogle Scholar
  17. 17.
    Ballatore C et al (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672CrossRefPubMedGoogle Scholar
  18. 18.
    Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis 15:157–168PubMedGoogle Scholar
  19. 19.
    Heneka MT et al (2007) Drug insight: Effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 3:496–504CrossRefPubMedGoogle Scholar
  20. 20.
    Risner ME et al (2006) Rosiglitazone in Alzheimer’s Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 6:246–254PubMedGoogle Scholar
  21. 21.
    Höglund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta amyloid peptide levels: Implications for Alzheimer‚s disease. CNS Drugs 21:449–462CrossRefPubMedGoogle Scholar
  22. 22.
    Haag MD et al (2009) Statins are associated with a reduced risk of Alzheimer’s disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80:13–17CrossRefPubMedGoogle Scholar
  23. 23.
    Luchsinger JA et al (2005) Aggregation of vascular risk factors and risk of incident Alzheimer’s disease. Neurology 65:545–551CrossRefPubMedGoogle Scholar
  24. 24.
    Kivipelto M et al (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer‚s disease. Arch Neurol 62:1556–1560CrossRefPubMedGoogle Scholar
  25. 25.
    Whitmer RA et al (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71:1057–1064CrossRefPubMedGoogle Scholar
  26. 26.
    Stranahan AM et al (2008) Diet induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18:1085–1088CrossRefPubMedGoogle Scholar
  27. 27.
    Cao D et al (2007) Intake of sucrose sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer’s disease. J Biol Chem 282:36275–36282CrossRefPubMedGoogle Scholar
  28. 28.
    Schröder H et al (2004) Adherence to the traditional mediterranean diet is inversively associated with body mass index and obesity in a spanish population. J Nutr 134:3355–3361PubMedGoogle Scholar
  29. 29.
    Scarmeas N et al (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66:216–225CrossRefPubMedGoogle Scholar
  30. 30.
    Rozzini L et al (2005) Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. Int J Geriatr Psychiatry 20:547–551CrossRefPubMedGoogle Scholar
  31. 31.
    Doody RS et al (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and globalfunction in patients with mild-to-moderate Alzheimer’s disease: A randomised, double-blind, placebo-controlled study. Lancet 372:207–215CrossRefPubMedGoogle Scholar
  32. 32.
    Moreira PI et al (2008) Alzheimer’s disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7:3–10CrossRefPubMedGoogle Scholar
  33. 33.
    IQWiG (2008) Nichtmedikamentöse Behandlung der Alzheimer Demenz, Vorbericht A05–19DGoogle Scholar
  34. 34.
    Karsten SL, Geschwind DH (2005) Exercise your amyloid. Cell 120:572–574CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinische NeurowissenschaftenKlinik und Poliklinik für Neurologie, Universität BonnBonnDeutschland
  2. 2.Deutsches Zentrum für Neurodegenerative ErkrankungenBonnDeutschland

Personalised recommendations